Senkyunolide HCAS# 94596-27-7 |
- Senkyunolide I
Catalog No.:BCN6353
CAS No.:94596-28-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 94596-27-7 | SDF | Download SDF |
| PubChem ID | 5321251 | Appearance | Oil |
| Formula | C12H16O4 | M.Wt | 224.3 |
| Type of Compound | Miscellaneous | Storage | Desiccate at -20°C |
| Synonyms | AC1NT0CA | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (3Z,6S,7R)-3-butylidene-6,7-dihydroxy-4,5,6,7-tetrahydro-2-benzofuran-1-one | ||
| SMILES | CCCC=C1C2=C(C(C(CC2)O)O)C(=O)O1 | ||
| Standard InChIKey | DQNGMIQSXNGHOA-RCBCECLLSA-N | ||
| Standard InChI | InChI=1S/C12H16O4/c1-2-3-4-9-7-5-6-8(13)11(14)10(7)12(15)16-9/h4,8,11,13-14H,2-3,5-6H2,1H3/b9-4-/t8-,11-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Senkyunolide H, senkyunolide I and ferulic acid can reduce the metamorphose damage of the RBC caused by ConA, the aggregation of the RBC also could be alleviated by them. 2. Senkyunolide H in cnidium rhizome may be a prototype for an anti-atherosclerotic drug. |
Senkyunolide H Dilution Calculator
Senkyunolide H Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.4583 mL | 22.2916 mL | 44.5831 mL | 89.1663 mL | 111.4579 mL |
| 5 mM | 0.8917 mL | 4.4583 mL | 8.9166 mL | 17.8333 mL | 22.2916 mL |
| 10 mM | 0.4458 mL | 2.2292 mL | 4.4583 mL | 8.9166 mL | 11.1458 mL |
| 50 mM | 0.0892 mL | 0.4458 mL | 0.8917 mL | 1.7833 mL | 2.2292 mL |
| 100 mM | 0.0446 mL | 0.2229 mL | 0.4458 mL | 0.8917 mL | 1.1146 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Parisyunnanoside B
Catalog No.:BCN2837
CAS No.:945865-37-2
- AA 29504
Catalog No.:BCC7829
CAS No.:945828-50-2
- XL019
Catalog No.:BCC2057
CAS No.:945755-56-6
- 7-O-ethyl-morroniside
Catalog No.:BCN3883
CAS No.:945721-10-8
- 6-Aldehydo-7-methoxyiso-ophiopogonanone B
Catalog No.:BCC8345
CAS No.:123941-06-0
- (R)-(+)-m-Nitrobiphenyline oxalate
Catalog No.:BCC7525
CAS No.:945618-97-3
- Pexmetinib (ARRY-614)
Catalog No.:BCC6509
CAS No.:945614-12-0
- AMG-900
Catalog No.:BCC2175
CAS No.:945595-80-2
- Levcromakalim
Catalog No.:BCC7039
CAS No.:94535-50-9
- 9(11),12-Oleanadien-3-ol
Catalog No.:BCN4499
CAS No.:94530-87-7
- Senkyunolide G
Catalog No.:BCC9143
CAS No.:94530-85-5
- Senkyunolide E
Catalog No.:BCC9142
CAS No.:94530-83-3
- Senkyunolide I
Catalog No.:BCN6353
CAS No.:94596-28-8
- LX-1031
Catalog No.:BCC1712
CAS No.:945976-76-1
- RO5126766(CH5126766)
Catalog No.:BCC6374
CAS No.:946128-88-7
- Mulberrofuran K
Catalog No.:BCN7188
CAS No.:94617-36-4
- RN 1734
Catalog No.:BCC7770
CAS No.:946387-07-1
- LY2409881
Catalog No.:BCC5650
CAS No.:946518-60-1
- Hyperectine
Catalog No.:BCN3406
CAS No.:94656-46-9
- MNI 137
Catalog No.:BCC6156
CAS No.:946619-21-2
- Rhodiolgin; Gossypetin-7-O-α-rhamnopyranoside
Catalog No.:BCC8247
CAS No.:94696-39-6
- Gypenoside XLVI
Catalog No.:BCN3863
CAS No.:94705-70-1
- PF 429242
Catalog No.:BCC6009
CAS No.:947303-87-9
- Fmoc-Aib-OH
Catalog No.:BCC3149
CAS No.:94744-50-0
Simultaneous determination of senkyunolide I and senkyunolide H in rat plasma by LC-MS: application to a comparative pharmacokinetic study in normal and migrainous rats after oral administration of Chuanxiong Rhizoma extract.[Pubmed:25620053]
Biomed Chromatogr. 2015 Sep;29(9):1297-303.
A selective liquid chromatographic-mass spectrometric method has been developed and validated for simultaneous determination of senkyunolide I (SEI) and Senkyunolide H (SEH) from Chuanxiong Rhizoma in rat plasma. Plasma samples were extracted by liquid-liquid extraction with ethyl acetate and separated on a Kromasil C18 column (250 x 4.6 mm, 5 microm), with methanol-water (55:45, v/v) as mobile phase. The linear range was 0.05-25 microg/mL for SEI and 0.01-5.0 microg/mL for SEH, with lower limits of quantitation of 0.05 and 0.01 microg/mL, respectively. Intra- and inter-day precision were within 10.0 and 9.8%, and the accuracies (relative errors) were <9.6 and 5.9%, with the mean extraction recoveries 81.0-86.6 and 80.5-85.0% for the two anayltes, respectively. The validated method was successfully applied to a comparative pharmacokinetic study of SEI and SEH in normal and migrainous rats after oral administration of Chuanxiong Rhizoma extract. The results indicated that there were obvious differences between normal and migrainous rats in the pharmacokinetic behavior after oral administration of Chuanxiong Rhizoma extract. The absorption of SEI and SEH were significantly increased in migrainous rats compared with normal rats.
[Preparation of ferulic acid, senkyunolide I and senkyunolide H from Ligusticum chuanxiong by preparative HPLC].[Pubmed:24066590]
Zhongguo Zhong Yao Za Zhi. 2013 Jun;38(12):1947-50.
Preparative HPLC was used to prepare ferulic acid, senkyunolide I and Senkyunolide H from Ligusticum chuanxiong. The separation was conducted on a Shim-Pack Prep-ODS (20.0 mm x 250 mm, 5 microm) column with the mobile phase of methanol-0.2% glacial acetic acid (50:50)at the flow rate of 5 mL x min(-1). The detection wavelength was 278 nm, and the purity of each compound was detected by HPLC analysis. Spectral data analyses including UV, ESI-MS and NMR were used to identify their structures. This method is simple, fast, which is suitable for preparation of standard reference of ferulic acid, senkyunolide I and Senkyunolide H from L. chuanxiong and can meet the requirement of new drug research and development.
Chemical structure-activity of cnidium rhizome-derived phthalides for the competence inhibition of proliferation in primary cultures of mouse aorta smooth muscle cells.[Pubmed:8107327]
Jpn J Pharmacol. 1993 Nov;63(3):353-9.
Inhibitory effects of cnidium rhizome-derived phthalides on competence and progression phases of fetal bovine serum (10%)-induced proliferation were compared in primary cultures of mouse aorta smooth muscle cells (SMC). Their potencies for the competence inhibition were in the order of senkyunolide L ((Z)-6-hydroxy-7-chloro-6,7-dihydroligustilide) > Senkyunolide H ((Z)-6,7-dihydroxy-6,7-dihydroligustilide) > senkyunolide J ((3S)-(E)-6,7-dihydroxy-3,6,7,8-tetrahydroligustilide) > senkyunolide I ((E)-6,7-dihydroxy-6,7-dihydroligustilide) > ligustilide = senkyunolide A ((3S)-3,8-dihydroligustilide) > butylidenephthalide. The order of their potencies for the progression inhibition was parallel with that for the competence inhibition. Senkyunolide L is considered to have been formed during the extraction of cnidium. These results demonstrate that the (Z)-6,7-dihydroxy isomer of the dihydroligustilide derivatives is essential for the anti-competent effect on proliferation of the SMC in primary culture. Senkyunolide H in cnidium rhizome may be a prototype for a new anti-atherosclerotic drug.
